The long-term trend of the EPS is a vital number as it helps understand the future potential of PLx Pharma. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 35.30 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for PLx Pharma since it indicates how well the business is allocating resources to benefit shareholders.



PLx Pharma is part of the biotechnology industry and is in the healthcare sector. The company CEO is Natasha Giordano. PLx Pharma Inc is a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard delivery system to provide safer and more effective aspirin products.

Previous Intraday Performance:

The PLXP shares had a previous change of -7.44% which opened at 4.81 and closed at 4.48. It moved to an intraday high of 5.10 and a low of 4.33.

SeekingAlpha:  Midday movers and shakers

Historical Performance:

Over the last five trading days, PLXP shares returned 6.16% and in the past 30 trading days it returned 14.58%. Over three months, it changed 25.82%. In one year it has changed -39.74% and within that year its 52-week high was 7.60 and its 52-week low was 1.00. PLXP stock is 348.00% above its 52 Week Low.

Our calculations result in a 200 day moving average of 3.81 and a 50 day moving average of 3.52. Right now, PLXP stock is trading 17.71% above its 200 day moving average.

SeekingAlpha:  Midday movers and shakers

Liquidity:

The company has a market cap of $39.2m with 8.7m shares outstanding and a float of 4.3m shares. Trading volume was 45,999 shares and has experienced an average volume of 92,228 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for PLx Pharma was -2.16 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.39.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.39
06-30-2018:  -0.30
03-31-2018:  -0.40
12-31-2017:  -0.48

Indicators Also to Watch:

Based on the latest filings, there is 51.20% of insider ownership and 26.80% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.



I calculated the beta to be 6.52

Business Wire:  Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -127.24%, return on assets is -34.56%, price-to-sales is 90.98 and price-to-book is 12.46.

Company Score Card:

Results are out of six:
 4  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here